Method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 51.55% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTIRONWOOD PHARMACEUTICALS INC's latest supported as-filed period reports revenue of $113.0M, 32.6% above the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 51.55% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 32.62% · CORE
Level · gp.fundamentals.operating_margin
Raw value 70.16% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 19.83% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 2.86% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -14.8% from the comparable as-filed period.
Net income changed +117.3% from the comparable as-filed period.
Operating income changed +75.0% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
IRWD · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001104659-26-091987SEC ↗8-KAug 6, 2026Period Aug 6, 20260001104659-26-091625SEC ↗4Jul 22, 2026Period Jul 20, 20260001193125-26-312410SEC ↗4Jul 9, 2026Period Jul 7, 20260001193125-26-299749SEC ↗8-KJun 18, 2026Period Jun 16, 20260001104659-26-075730SEC ↗4Jun 17, 2026Period Jun 16, 20260001193125-26-274301SEC ↗4Jun 17, 2026Period Jun 16, 20260001193125-26-274292SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 20, 2026Filed Jul 22, 2026 | Silber JeffreySVP, CMO, Head-Res&Drug | Grant Or AwardDirect | 137,036 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating margin changed +1699 basis points from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Research & development changed -4.1% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Revenue changed +32.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Selling, general & administrative changed -32.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-274288